Heart Rate Reduction by Ivabradine Reduces Diastolic Dysfunction and Cardiac Fibrosis | Zendy

David Busseuil | Zendy; Yanfen Shi | Zendy; Mélanie Mecteau | Zendy; Geneviève Brand | Zendy; MarcAntoine Gillis | Zendy; Éric Thorin | Zendy; Caroline Asselin | Zendy; Philippe Roméo | Zendy; Tack Ki Leung | Zendy; Jean-Gilles Latour | Zendy; Christine Des Rosiers | Zendy; Muriel Bouly | Zendy; Éric Rhéaume | Zendy; JeanClaude Tardif | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Heart Rate Reduction by Ivabradine Reduces Diastolic Dysfunction and Cardiac Fibrosis

Author(s) -

David Busseuil,

Yanfen Shi,

Mélanie Mecteau,

Geneviève Brand,

MarcAntoine Gillis,

Éric Thorin,

Caroline Asselin,

Philippe Roméo,

Tack Ki Leung,

Jean-Gilles Latour,

Christine Des Rosiers,

Muriel Bouly,

Éric Rhéaume,

JeanClaude Tardif

Publication year - 2010

Publication title -

cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.547

H-Index - 63

eISSN - 1421-9751

pISSN - 0008-6312

DOI - 10.1159/000322905

Subject(s) - medicine , cardiology , diastole , heart failure , aldosterone , angiotensin ii , ivabradine , cardiac function curve , cardiac fibrosis , fibrosis , endocrinology , myocardial fibrosis , heart rate , blood pressure

To determine if heart rate (HR) reduction with ivabradine (IVA), a selective inhibitor of the pacemaker I(f) current, prevents cardiac dysfunction associated with dyslipidemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research